[1] TUNBRIDGE W M, EVERED D C, HALL R, et al. The spectrum of thyroid disease in a community: the Whickham survey[J]. Clin Endocrinol, 1977, 7(6): 481-493.
[2] HOLLOWELL J G, STAEHLING N W, FLANDERS W D, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)[J]. J Clin Endocrinol Metab, 2002, 87(2): 489-499.
[3] GARMENDIA MADARIAGA A, SANTOS PALACIOS S, GUILLéN-GRIMA F, et al. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis[J]. J Clin Endocrinol Metab, 2014, 99(3): 923-931.
[4] CARLÉ A, ANDERSEN S L, BOELAERT K, et al. Management of endocrine disease: Subclinical thyrotoxicosis: prevalence, causes and choice of therapy[J]. Eur J Endocrinol, 2017, 176(6): R325-R337.
[5] AGHINI-LOMBARDI F, ANTONANGELI L, MARTINO E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey[J]. J Clin Endocrinol Metab, 1999, 84(2): 561-566.
[6] LAURBERG P, PEDERSEN K M, HREIDARSSON A, et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark[J]. J Clin Endocrinol Metab, 1998, 83(3): 765-769.
[7] SHAN Z, CHEN L, LIAN X, et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities[J]. Thyroid, 2016, 26(8): 1125-1130.
[8] LI Y, TENG D, BA J, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4):568-579.
[9] BOELAERT K. Thyroid dysfunction in the elderly[J]. Nat Rev Endocrinol, 2013, 9(4):194-204.
[10]COHEN-LEHMAN J, DAHL P, DANZI S, et al. Effects of amiodarone therapy on thyroid function[J]. Nat Rev Endocrinol, 2010, 6(1): 34-41.
[11]KORNELIUS E, CHIOU J Y, YANG Y S, et al. Iodinated contrast media increased the risk of thyroid dysfunction: a 6-year retrospective cohort study[J]. J Clin Endocrinol Metab, 2015, 100(9): 3372-3379.
[12]MCCAHON D, HAQUE M S, PARLE J, et al. Subclinical thyroid dysfunction symptoms in older adults: cross-sectional study in UK primary care[J].Br J Gen Pract, 2020, 70(692): e208-e214.
[13]ROSARIO P W, CARVALHO M, CALSOLARI M R. Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism[J]. Clin Endocrinol: Oxf, 2016, 85(1): 132-136.
[14]VADIVELOO T, DONNAN P T, COCHRANE L, et al. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism[J]. J Clin Endocrinol Metab, 2011, 96(5): 1344-1351.
[15]SELMER C, OLESEN J B, HANSEN M L, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study[J]. J Clin Endocrinol Metab, 2014, 99(7): 2372-2382.
[16]ASVOLD B O, BJORO T, PLATOU C, et al. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway[J]. Clin Endocrinol: Oxf, 2012, 77(6): 911-917.
[17]ELLERVIK C, ROSELLI C, CHRISTOPHERSEN I E, et al. Assessment of the relationship between genetic determinants of thyroid function and atrial fibrillation: A mendelian randomization study[J]. JAMA Cardiol, 2019, 4(2): 144-152.
[18]COLLET T H, GUSSEKLOO J, BAUER D C, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality[J]. Arch Intern Med, 2012, 172(10): 799-809.
[19]SOHN S Y, LEE E, LEE M K, et al. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: Meta-Analysis and Systematic Review of Cohort Studies[J]. Endocrinol Metab (Seoul), 2020, 35(4): 786-800.
[20]DU PUY R S, POORTVLIET R K E, MOOIJAART S P, et al. Outcomes of thyroid dysfunction in people aged eighty years and older: an individual patient data meta-analysis of four prospective studies (towards understanding longitudinal international older people studies consortium)[J]. Thyroid, 2020. DOI: 10.1089/THY.2020.0567.
[21]AWEIMER A, EL-BATTRAWY I, AKIN I, et al. Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study[J]. J Intern Med, 2020. DOI: 10.1111/JOIM.13189.
[22]VADIVELOO T, DONNAN P T, COCHRANE L, et al. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism[J]. J Clin Endocrinol Metab, 2011, 96(1): E1-8.
[23]DAS G, OJEWUYI T A, BAGLIONI P, et al. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism[J]. Clin Endocrinol, 2012, 77(1): 146-151.
[24]ELTE J W, BUSSEMAKER J K, HAAK A. The natural history of euthyroid multinodular goitre[J]. Postgrad Med J, 1990, 66(773): 186-190.
[25]BELFIORE A, SAVA L, RUNELLO F, et al. Solitary autonomously functioning thyroid nodules and iodine deficiency[J]. J Clin Endocrinol Metab, 1983, 56(2): 283-287.
[26]RIEBEN C, SEGNA D, DA COSTA B R, et al. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies[J]. J Clin Endocrinol Metab, 2016, 101(12): 4945-4954.
[27]VIRGINI V S, WIJSMAN L W, RODONDI N, et al. Subclinical thyroid dysfunction and functional capacity among elderly [J]. Thyroid, 2014, 24(2): 208-214.
[28]YAN Z, HUANG H, LI J, et al. Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies [J]. Osteoporos Int, 2016, 27(1): 115-125.
[29]TAUCHMANOVA L, NUZZO V, DEL PUENTE A, et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism[J]. Maturitas, 2004, 48(3): 299-306.
[30]FLYNN R W, BONELLIE S R, JUNG R T, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy[J]. J Clin Endocrinol Metab, 2010, 95(1): 186-193.
[31]BURCH H B, COOPER D S. Management of Graves disease: a review[J]. JAMA, 2015, 314(23): 2544-2554.
[32]ROSS D S, BURCH H B, COOPER D S, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421. |
